Lymphoma Hub
Avsnitt

What is the rationale for the development of tandem CAR T-cell therapies?

Lymphoma Hub
Dela

The Lymphoma Hub was pleased to speak with Peter Borchmann, University Hospital Cologne, DE. We asked, What is the rationale for the development of tandem chimeric antigen receptor (CAR) T-cell therapies?


Intended for healthcare professionals. This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Scientific Education Support. Innehållet i podden är skapat av Scientific Education Support och inte av, eller tillsammans med, Poddtoppen.